Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 07/10/09 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
14 | |
| 06/25/09 | UPLOAD | SEC-generated letter |
|
7 | |
| 06/02/09 | 8-K | Current report filing |
|
9 | |
| 05/21/09 | 8-K | Current report filing |
|
3 | |
| 05/05/09 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
19 | |
| 03/27/09 | 8-K | Current report filing |
|
5 | |
| 03/06/09 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
51 | |
| 11/14/08 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
24 | |
| 10/10/08 | 5 | Annual statement of changes in beneficial ownership of securities |
|
2 | |
| 10/06/08 | 40-17G | Fidelity bond filed pursuant to Rule 17g1(g)(1) of the Investment Company Act of 1940 |
|
4 |
